Irish comedian and body positivity advocate Laura O’Mahony has revealed that her decision to use GLP-1 weight-loss medication led to a significant loss of followers and supporters. Speaking via the Irish Examiner, O’Mahony addressed the tension between her public identity as a “beacon of body positivity” and her personal health choices.
This isn’t just a story about one woman’s Instagram feed; it is a glimpse into a massive cultural pivot. For years, the entertainment and fashion industries shifted toward radical inclusivity, championing a “come as you are” ethos. Now, the arrival of semaglutide-based “jabs” is creating a volatile friction point between the body positivity movement and the biological allure of rapid weight loss.
The Bottom Line
- The Conflict: Laura O’Mahony experienced a backlash from followers who felt her use of weight-loss medication betrayed her status as a body-positive icon.
- The Industry Shift: The “skinny jab” phenomenon is reversing years of progress in fashion and media inclusivity, with a noted return to “heroin chic” aesthetics in modeling.
- The Cultural Paradox: Celebrities are increasingly using GLP-1s to “destigmatize” the medication while simultaneously risking the alienation of the audiences who loved them for their non-traditional bodies.
The High Cost of the ‘Skinny Jab’ Paradox
For O’Mahony, the fallout was immediate. In her discussion with the Irish Examiner, she noted that opting for the medication sent a lot of people away
. It is the ultimate modern celebrity trap: the public demands “authenticity,” but that authenticity is often tethered to a specific, curated version of a person’s identity. When O’Mahony shifted her physical form via pharmaceutical intervention, the “brand” of the body-positive comedian suddenly felt, to some, like a contradiction.
But here is the kicker: this isn’t happening in a vacuum. We are seeing a systemic “unlearning” of the inclusivity era. From the halls of Vogue to the casting offices of major streaming platforms, the gravitational pull of thinness is returning with a vengeance.
The economics of this shift are staggering. We aren’t just talking about a few lost followers; we are talking about a pivot in consumer behavior that affects everything from apparel sizing to brand partnership valuations. When a “plus-size” icon loses weight, the brands that built their marketing around “inclusive sizing” face a crisis of identity and inventory.
The Erosion of Inclusivity in High Fashion
The industry-wide ripple effect is most evident in the modeling world. After a brief window where figures like Ashley Graham and Lizzo broke the glass ceiling of the “sample size,” the tide is turning. Recent reports indicate a visible decrease in mid- and plus-size representation on runways as the accessibility of GLP-1s makes “the look” achievable via prescription rather than genetics.
This shift is creating a dangerous feedback loop. As more talent adopts these medications, the “standard” for beauty resets, effectively erasing the visibility of those who cannot or will not use the drugs. It’s a return to a rigid aesthetic standard, powered by a needle.
| Metric | Pre-GLP-1 Era (2018-2022) | The “Jab” Era (2023-2026) |
|---|---|---|
| Fashion Focus | Radical Inclusivity / Body Positivity | Return to “Sleek” / Precision Weight Loss |
| Celebrity Narrative | “Loving your curves” | “Destigmatizing medical weight loss” |
| Market Trend | Growth in Plus-Size Apparel | Shift toward versatile, “changing-body” styles |
The ‘Destigmatization’ Defense
To navigate this, celebrities are pivoting their language. You’ll notice a trend: stars no longer talk about “getting skinny”; they talk about “health journeys” and “medical necessity.” Serena Williams, for example, has been open about using GLP-1s to destigmatize the medication
, framing the choice as a tool for wellness rather than a quest for a specific silhouette.
However, the cultural critics are not buying the PR spin. The tension lies in the fact that these drugs are often used for aesthetic goals rather than the clinical obesity they were designed to treat. This creates a perceived betrayal for audiences who felt that the body positivity movement was a sanctuary from the very pressures these drugs amplify.
“The danger of the ‘celebrity effect’ with GLP-1s is that it transforms a medical intervention into a social requirement. When the people who told us it was okay to be larger suddenly change their own shapes, it validates the very shame the body positivity movement sought to dismantle.” Cultural Analyst, Media Trends Group
The New Brand Management Playbook
So, where does this abandon creators like O’Mahony? In the current creator economy, the “pivot” is the only way to survive. The strategy is no longer about maintaining a static image, but about documenting the transition. By being honest about the “feedback” and the loss of followers, O’Mahony is attempting to bridge the gap between her past advocacy and her current reality.
But let’s be real: the math of the attention economy is brutal. Brands that once sought out “relatable” bodies are now eyeing the “transformation” narrative. The money is shifting from the *celebration* of the body to the *optimization* of the body. We are moving from an era of “You are enough” to an era of “You can be better.”
O’Mahony’s experience is a canary in the coal mine. It suggests that while the world may have embraced inclusivity, that embrace was conditional—contingent on the absence of a “magic pill.” Now that the pill exists, the social contract of body positivity is being rewritten in real-time.
Do you consider the use of weight-loss medication by body-positive icons is a betrayal of the movement, or is it simply a personal health choice that the public should respect? Let us know in the comments below.
